Current Research Opportunities
Since 2008, nearly 8,000 men and women have participated in over a dozen RMA clinical trials aimed at improving patient outcomes.
Our Research Program
Over the years, RMA has given away more than 1,000 free IVF cycles and more than 780 free embryo screenings as part of its research program. This is an investment we make to improve patient outcomes and continue to set evidence-based standards in reproductive medicine. Below you will find a list of our current research opportunities and past study opportunities our patients have been involved with.
Current Research Opportunities
Please note that eligibility cannot be assessed or guaranteed based on the below information until a new patient visit and diagnostic work up has been completed.
The objective of the Grow Study is to determine if personalized low dose hCG dosing as a possible treatment to help obtain a serum (blood) hCG level greater than 0.64mIU/ml improves IVF outcomes, specifically implantation rates.
Inclusion Criteria
- Undergoing IVF cycle with Pre-implantation
- Genetic Testing for Aneuploidy (PGT-A)
- Planned subsequent single Frozen Embryo Transfer (FET) cycle
- No prior failed or canceled IVF cycle history
Benefit to Participants
Participants in this study may receive individualized “LH effect” dosing along with free, low dose hCG medication, a cost savings of $149 per vial. Another benefit is being a part of a trial that may change the future of reproductive technology while possibly improving your personal outcome and outcomes for future IVF patients.
The purpose of this study is to determine and better understand the endometrial (uterine lining) gene expression and how it impacts embryo implantation.
Inclusion Criteria
- You have been diagnosed with infertility
- You have never undergone an IVF cycle
- You are a non-smoker with no major medical issues
- You do not have a history of abnormal uterine bleeding
- You have not had uterine surgery in the last 3 months
- You have a BMI lower than 35
Benefit to Participants
Participants who complete the study will receive free genetic embryo testing, or PGT-SEQ for aneuploidy, during their IVF cycle. In addition, there is the benefit of potentially helping future patients experiencing implantation failure.
The purpose of this study is to characterize the microbiome of the female reproductive tract and gastrointestinal tract as well as the male reproductive tract in patients and partners undergoing IVF and determine if there are any associations with pregnancy outcomes.
Inclusion Criteria
Women less than 45 years old and male partners less than 60 years old proceeding with an IVF cycle with Pre-implantation Genetic Testing for Aneuploidy (PGT-A) and Single Embryo Transfer (SET).
Exclusion Criteria
- >1 prior failed IVF cycle
- Third-party reproduction
- Cryopreserved sperm
- Mullerian anomalies
- Submucosal fibroids
- Communicating hydrosalpinx
Benefit to Participants
No direct benefit to participants outside of potentially helping future couples seeking treatment.